Compagnie Lombard Odier SCmA Purchases New Stake in Amgen Inc. (NASDAQ:AMGN)

Compagnie Lombard Odier SCmA bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 210,896 shares of the medical research company's stock, valued at approximately $65,705,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Centricity Wealth Management LLC purchased a new stake in Amgen during the fourth quarter worth $25,000. Pinney & Scofield Inc. purchased a new stake in Amgen during the 4th quarter worth approximately $26,000. Ritter Daniher Financial Advisory LLC DE lifted its holdings in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the 4th quarter worth approximately $34,000. Finally, Atala Financial Inc acquired a new stake in Amgen in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.76% of the company's stock.

Amgen Stock Performance

Shares of Amgen stock traded up $5.48 during trading on Thursday, hitting $297.29. 2,159,678 shares of the stock were exchanged, compared to its average volume of 2,814,397. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market capitalization of $159.85 billion, a price-to-earnings ratio of 39.38, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a fifty day moving average price of $280.88 and a 200-day moving average price of $285.46. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.96 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. UBS Group reaffirmed a "neutral" rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Mizuho lifted their price objective on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. Finally, Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.